비전이성 유방암 여성의 화학요법에 의한 모발변화와 탈모, 피부노화 및 손발톱변화에 관한 연구
비전이성 유방암 여성의 화학요법 유발 모발 변화 및 탈모증, 피부 노화 및 손발톱 변화에 대한 전향적 종단 연구
The purpose of this study is to see how many patients develop hair, skin and nail changes due to cancer treatments. The investigators would like to study the clinical factors, genetic markers, and impact on patients' health-related quality of life to learn more about who is at greater risk. We trust that the study will improve our understanding of how cancer patients feel about their skin, hair, and nail conditions. This information will help us determine the burden on breast cancer patients and survivors. It will also help us learn how to prevent these conditions and it may improve the way we treat them and counsel patients.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 장소
-
-
New York
-
New York, New York, 미국, 10021
- Memorial Sloan Kettering Cancer Center
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
MSKCC clinics
설명
Inclusion Criteria:
- Women newly diagnosed with non-metastatic breast cancer (stage 0-III, any receptor type) at the time of starting chemotherapy (dd-AC-T, CMF, Newer Combination Regimens) or endocrine therapy (tamoxifen, anastrozole, letrozole, exemestane)
- Women ≥ 18 years at the time of enrollment into the study
- Able to communicate in English and participate in the informed consent process
- Able to comply with the follow-up visits, assessments, answering questionnaires
Exclusion Criteria:
- Metastatic breast cancer
- Follow-up care/visits not scheduled at MSKCC
- Any current alopecia especially due to an active scalp and/or hair disorder (e.g. alopecia areata), or a pre-existing condition with sequelae (e.g. scarring alopecia)
- Currently active or uncontrolled medical condition [e.g. thyroid disorder, auto-immune connective tissue disease (e.g. SLE), BMT complications (GVHD)] or medication intake (e.g. HRT), affecting scalp hair
- Prior systemic treatment for any malignancy
- Active secondary cancer requiring cytotoxic chemotherapy
- Planned (or a history of) radiation therapy to the head
- Vulnerable populations [e.g. decisionally impaired (cognitive, psychiatric), terminally ill, prisoners], or patients who, in the opinion of the investigator have a condition that precludes their ability to provide an informed consent
- Men
Volunteer Inclusion Criteria:
- Post menopausal women, with menopausal status defined as (per self report):
- Bilateral salpingo-oophorectomy independent of age
- If natural menopause, age ≥ 50 with cessation of menses for at least 12 months
- Or premenopausal women with premenopausal status defined as <53 years of age with no cessation of menses
- Able to communicate in English and participate in the informed consent process
- Able to comply with the baseline assessments and answering questionnaires
- Women >/= 18 years at the time of enrollment into the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: CASE_CONTROL
- 시간 관점: RETROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Patients having CYTOTOXIC CHEMOTHERAPY
Participants will undergo study related assessments and the appropriate HRQoL questionnaires will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for (clinically indicated) standard-of-care visits. Initially, these visits will be coinciding with the appropriate chemotherapy dosing cycles (as applicable to select study cohorts), and subsequently they will be performed during the standard-of-care follow-up visits. |
(only once, preferably at baseline) |
|
Patients having ENDOCRINE THERAPY
Participants will undergo study related assessments and Medical and Personal History Questionnaire data collection forms and the appropriate HRQoL questionnaires, will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for standard-of-care visits. Initially, these visits will be coinciding with the appropriate therapy and subsequently they will be performed during the standard-of-care follow-up visits. |
(only once, preferably at baseline) |
|
COMPARATOR (menopausal women)
Menopausal women will include unrelated visitors accompanying breast cancer patients (e.g. friends) attending the breast medicine or dermatology clinics, or female employees of MSKCC. There will be no follow-up visits (after baseline) for participants in the comparator cohort. |
(only once, preferably at baseline) |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of persistent alopecia
기간: 1 year
|
as assessed clinically and by phototrichogram assessments, among women exposed to cytotoxic chemotherapy |
1 year
|
|
Incidence of alopecia
기간: 1 year
|
as assessed clinically and by phototrichogram assessments, among women exposed to endocrine therapies |
1 year
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Alina Markova, MD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 15-198
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .